Feed excerpt — reported by STAT News
Grey market stem cells pose many of the same issues as peptides, a treatment that gained a new level of FDA legitimacy after being embraced by MAHA.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →